The new edition of the 2016 World Health Organization (WHO) classification system for
tumors of the hematopoietic and lymphoid tissues was published in September 2017. Under …

The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part
elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin …

The classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPN)
consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a …

PURPOSE Targeting the BCL-XL pathway has demonstrated the ability to overcome Janus
kinase inhibitor resistance in preclinical models. This phase II trial investigated the efficacy …

Background Approximately 50 to 60% of patients with essential thrombocythemia or primary
myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to …

Background Somatic mutations in the Janus kinase 2 gene (JAK2) occur in many
myeloproliferative neoplasms, but the molecular pathogenesis of myeloproliferative …

Abstract BCR:: ABL1-negative myeloproliferative neoplasms (MPNs) are clonal diseases
originating from a single hematopoietic stem cell that cause excessive production of mature …

Genetic and functional studies underscore the central role of JAK/STAT signaling in
myeloproliferative neoplasms (MPNs). However, the mechanisms that mediate …

The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a
heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera …

JAKs and STATs in Immunity, Immunodeficiency, and Cancer | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …